Application of DKK4 gene and coding protein thereof in preparation of medicament

Abstract

The invention provides application of a DKK4 gene and a coding protein thereof in preparation of a medicament, in particular application in preparation of a medicament for detecting or treating a gastrointestinal stromal tumor (GIST). The medicament is a detection medicament consisting of a DKK4 antibody serving as an active ingredient and a medicinal carrier or consisting of a DKK4 specific primer serving as an active ingredient and a medicinal carrier. The medicament is a detection kit prepared from the DKK4 antibody or the specific primer thereof serving as the active ingredient and a medicinal carrier. Early diagnosis of the GIST or prognosis of a GIST patient accepting operative treatment is realized by using the detection based on the DKK gene and the product thereof in serum / tissues; through high-flux chip screening established on the gene level, real-time quantitative polymerase chain reaction (PCR) verification and large clinical sample verification on the protein level, the results are reliable; according to the experimental results, the DKK4 can remarkably distinguish tumor and non-tumor, high-risk tumor and low-risk tumor on both the gene level and the protein level, and the repeatability of the results is high; and the difference of the expression quantity of the DKK4 gene between different groups is huge, and the DKK4 gene has a good clinical application value.

Description

technical field [0001] The invention relates to medicine, in particular to the application of DKK4 gene and its encoded protein in preparing medicine, especially the application of DKK4 gene and its encoded protein in preparing medicine for detecting or treating gastrointestinal stromal tumor. Background technique [0002] Gastrointestinal stromal tumor (GIST) is the most common tumor of mesenchymal origin in the gastrointestinal tract, mainly occurring in the stomach (about 70%). In recent years, the incidence of GIST has been increasing rapidly year by year. Epidemiological statistics at home and abroad in recent years show that the incidence of GIST exceeds 20 / million people / year. The epidemiological survey in China in 2009 showed that the incidence rate reached about 30 per million people per year. It is estimated that the number of new cases in China can reach about 40,000 to 50,000 per year. GIST has become the most common malignant tumor in the digestive tract next t...

AI Technical Summary

Problems solved by technology

However, there are also some problems in the clinical practice of targeted drug therapy application: 1. About 5-10% of patients are primary resistant to imatinib, and most of the patients who are effective to initial treatment with imatinib Patients will eventually inevitably develop drug resistance, and drug resistance mostly occurs within 6 months to 2 years after the initiation of initial treatment; 2. At present, patients with high recurrence risk of GIST who receive adjuvant imatinib therapy for a certain period of time after surgery have achieved However, the selection of suitable population for adjuvant therapy is always controversial. Relaxation of treatment indications will inevitably lead to waste of medical resources and increase the occurrence of drug resistance; excessively strict indications will also cause some patients to miss the reasonable treatment they should receive. If there are more objective and reasonable indicators for judging the recurrence risk of GIST patients, it will greatly benefit the prevention and treatment of GIST

There is no corresponding research on the relationship between the DKK4 gene and the occurrence of gastrointestinal stromal tumors before

Images